FindTrial
Sign In

The association of single nucleotide polymorphism with response to anti-vascular endothelial growth factor treatment in Chinese polypoidal choroidal vasculopathy patients

The association of single nucleotide polymorphism with response to anti-vascular endothelial growth factor treatment in Chinese polypoidal choroidal vasculopathy patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049698
Enrollment
Unknown
Registered
2021-08-08
Start date
2021-08-16
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polypoidal choroidal vasculopathy

Interventions

Anti-VEGF treatment group:Intravenous injection of aflibercept

Sponsors

Chinese Academy of Medical Sciences Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. PCV patients: that is, polypoid hyperfluorescence within 6 minutes of indocyanine green angiography (ICGA) injection of contrast agent, with or without abnormal branching vascular network; 2. No treatment or no anti-VEGF treatment within 6 months; 3. Voluntarily participate in this study and sign the informed consent; 4. There are long-term follow-up conditions in the included hospital.

Exclusion criteria

Exclusion criteria: 1. Combined with other serious eye diseases; 2. Combined with serious systemic diseases, and the current clinical routine treatment has contraindications; 3. There is no long-term follow-up condition.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;Intraocular pressure;Fundus image;OCT;ICGA;Aqueous humour test;Blood test;—

Countries

China

Contacts

Public ContactChen Youxin

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

chenyx@pumch.cn+86 17600213506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026